Hepatitis B - Pipeline Review, H2 2015

Date: November 30, 2015
Pages: 385
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: HB2A719C22BEN
Leaflet:

Download PDF Leaflet

Hepatitis B - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Hepatitis B - Pipeline Review, H2 2015’, provides an overview of the Hepatitis B’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis B and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Hepatitis B
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Hepatitis B and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Hepatitis B products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hepatitis B pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hepatitis B
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hepatitis B pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Hepatitis B Overview
Therapeutics Development
Hepatitis B - Therapeutics under Development by Companies
Hepatitis B - Therapeutics under Investigation by Universities/Institutes
Hepatitis B - Pipeline Products Glance
Hepatitis B - Products under Development by Companies
Hepatitis B - Products under Investigation by Universities/Institutes
Hepatitis B - Companies Involved in Therapeutics Development
Hepatitis B - Therapeutics Assessment
Drug Profiles
Hepatitis B - Recent Pipeline Updates
Hepatitis B - Dormant Projects
Hepatitis B - Discontinued Products
Hepatitis B - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Hepatitis B, H2 2015
Number of Products under Development for Hepatitis B - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd.1)
Number of Products under Development by Companies, H2 2015 (Contd.2)
Number of Products under Development by Companies, H2 2015 (Contd.3)
Number of Products under Development by Companies, H2 2015 (Contd.4)
Number of Products under Development by Companies, H2 2015 (Contd.5)
Number of Products under Development by Companies, H2 2015 (Contd.6)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd.1)
Products under Development by Companies, H2 2015 (Contd.2)
Products under Development by Companies, H2 2015 (Contd.3)
Products under Development by Companies, H2 2015 (Contd.4)
Products under Development by Companies, H2 2015 (Contd.5)
Products under Development by Companies, H2 2015 (Contd.6)
Products under Development by Companies, H2 2015 (Contd.7)
Products under Development by Companies, H2 2015 (Contd.8)
Products under Investigation by Universities/Institutes, H2 2015
Hepatitis B - Pipeline by Abivax S.A., H2 2015
Hepatitis B - Pipeline by AiCuris GmbH & Co. KG, H2 2015
Hepatitis B - Pipeline by AIMM Therapeutics B.V., H2 2015
Hepatitis B - Pipeline by Akshaya Bio Inc., H2 2015
Hepatitis B - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2015
Hepatitis B - Pipeline by AlphaMab Co., Ltd, H2 2015
Hepatitis B - Pipeline by Altimmune, Inc., H2 2015
Hepatitis B - Pipeline by AltraVax Inc., H2 2015
Hepatitis B - Pipeline by Amarna Therapeutics B.V., H2 2015
Hepatitis B - Pipeline by Arbutus Biopharma Corporation, H2 2015
Hepatitis B - Pipeline by Arrowhead Research Corporation, H2 2015
Hepatitis B - Pipeline by Assembly Biosciences, Inc., H2 2015
Hepatitis B - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2015
Hepatitis B - Pipeline by Benitec Biopharma Limited, H2 2015
Hepatitis B - Pipeline by BioDiem Ltd, H2 2015
Hepatitis B - Pipeline by Biogenomics Limited, H2 2015
Hepatitis B - Pipeline by Biological E. Limited, H2 2015
Hepatitis B - Pipeline by BioStar Pharmaceuticals, Inc., H2 2015
Hepatitis B - Pipeline by Bolder Biotechnology, Inc., H2 2015
Hepatitis B - Pipeline by Bukwang Pharm.Co., Ltd., H2 2015
Hepatitis B - Pipeline by CaroGen Corporation, H2 2015
Hepatitis B - Pipeline by CEL-SCI Corporation, H2 2015
Hepatitis B - Pipeline by Celltrion, Inc., H2 2015
Hepatitis B - Pipeline by Chimerix, Inc., H2 2015
Hepatitis B - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H2 2015
Hepatitis B - Pipeline by ChronTech Pharma AB, H2 2015
Hepatitis B - Pipeline by Cocrystal Pharma, Inc., H2 2015
Hepatitis B - Pipeline by Cytos Biotechnology AG, H2 2015
Hepatitis B - Pipeline by CyTuVax B.V., H2 2015
Hepatitis B - Pipeline by Dong-A ST Co., Ltd., H2 2015
Hepatitis B - Pipeline by Dynavax Technologies Corporation, H2 2015
Hepatitis B - Pipeline by Ensemble Therapeutics Corporation, H2 2015
Hepatitis B - Pipeline by Enyo Pharma S.A.S., H2 2015
Hepatitis B - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Hepatitis B - Pipeline by GeneCure LLC, H2 2015
Hepatitis B - Pipeline by Genexine, Inc., H2 2015
Hepatitis B - Pipeline by Gilead Sciences, Inc., H2 2015
Hepatitis B - Pipeline by GlaxoSmithKline Plc, H2 2015
Hepatitis B - Pipeline by Green Cross Corporation, H2 2015
Hepatitis B - Pipeline by HEC Pharm Co., Ltd., H2 2015
Hepatitis B - Pipeline by Humabs BioMed SA, H2 2015
Hepatitis B - Pipeline by Ildong Pharmaceutical Co., Ltd., H2 2015
Hepatitis B - Pipeline by Immunotope, Inc., H2 2015
Hepatitis B - Pipeline by Immunovaccine, Inc., H2 2015
Hepatitis B - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2015
Hepatitis B - Pipeline by Indian Immunologicals Limited, H2 2015
Hepatitis B - Pipeline by iQur Limited, H2 2015
Hepatitis B - Pipeline by ISA Pharmaceuticals B.V., H2 2015
Hepatitis B - Pipeline by Isis Pharmaceuticals, Inc., H2 2015
Hepatitis B - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H2 2015
Hepatitis B - Pipeline by Johnson & Johnson, H2 2015
Hepatitis B - Pipeline by KAEL-GemVax Co., Ltd., H2 2015
Hepatitis B - Pipeline by Kineta, Inc., H2 2015
Hepatitis B - Pipeline by Leukocare AG, H2 2015
Hepatitis B - Pipeline by LG Life Science LTD., H2 2015
Hepatitis B - Pipeline by Ligand Pharmaceuticals, Inc., H2 2015
Hepatitis B - Pipeline by Mologen AG, H2 2015
Hepatitis B - Pipeline by Mucosis B.V., H2 2015
Hepatitis B - Pipeline by MultiCell Technologies, Inc., H2 2015
Hepatitis B - Pipeline by Novira Therapeutics, Inc., H2 2015
Hepatitis B - Pipeline by Panacea Biotec Limited, H2 2015
Hepatitis B - Pipeline by Pfenex Inc., H2 2015
Hepatitis B - Pipeline by PharmaEssentia Corporation, H2 2015
Hepatitis B - Pipeline by Profectus BioSciences, Inc., H2 2015
Hepatitis B - Pipeline by Redx Pharma Plc, H2 2015
Hepatitis B - Pipeline by REPLICor Inc., H2 2015
Hepatitis B - Pipeline by Romark Laboratories, L.C., H2 2015
Hepatitis B - Pipeline by Sanofi Pasteur SA, H2 2015
Hepatitis B - Pipeline by SEEK Group, H2 2015
Hepatitis B - Pipeline by Sinovac Biotech Ltd., H2 2015
Hepatitis B - Pipeline by Spring Bank Pharmaceuticals, Inc., H2 2015
Hepatitis B - Pipeline by TCM Biotech International Corp, H2 2015
Hepatitis B - Pipeline by TetraLogic Pharmaceuticals, H2 2015
Hepatitis B - Pipeline by TGV-Laboratories, H2 2015
Hepatitis B - Pipeline by Theravectys SA, H2 2015
Hepatitis B - Pipeline by Transgene SA, H2 2015
Hepatitis B - Pipeline by UAB Profarma, H2 2015
Hepatitis B - Pipeline by Vaxine Pty Ltd, H2 2015
Hepatitis B - Pipeline by Viriom Ltd., H2 2015
Hepatitis B - Pipeline by VLP Biotech, Inc., H2 2015
Hepatitis B - Pipeline by WaterStone Pharmaceuticals, Inc., H2 2015
Hepatitis B - Pipeline by Zydus Cadila Healthcare Limited, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Hepatitis B Therapeutics - Recent Pipeline Updates, H2 2015
Hepatitis B - Dormant Projects, H2 2015
Hepatitis B - Dormant Projects (Contd.1), H2 2015
Hepatitis B - Dormant Projects (Contd.2), H2 2015
Hepatitis B - Dormant Projects (Contd.3), H2 2015
Hepatitis B - Dormant Projects (Contd.4), H2 2015
Hepatitis B - Dormant Projects (Contd.5), H2 2015
Hepatitis B - Dormant Projects (Contd.6), H2 2015
Hepatitis B - Dormant Projects (Contd.7), H2 2015
Hepatitis B - Dormant Projects (Contd.8), H2 2015
Hepatitis B - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Hepatitis B, H2 2015
Number of Products under Development for Hepatitis B - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

Abivax S.A.
AiCuris GmbH & Co. KG
AIMM Therapeutics B.V.
Akshaya Bio Inc.
Alnylam Pharmaceuticals, Inc.
AlphaMab Co., Ltd
Altimmune, Inc.
AltraVax Inc.
Amarna Therapeutics B.V.
Arbutus Biopharma Corporation
Arrowhead Research Corporation
Assembly Biosciences, Inc.
Beijing Minhai Biotechnology Co., Ltd
Benitec Biopharma Limited
BioDiem Ltd
Biogenomics Limited
Biological E. Limited
BioStar Pharmaceuticals, Inc.
Bolder Biotechnology, Inc.
Bukwang Pharm.Co., Ltd.
CaroGen Corporation
CEL-SCI Corporation
Celltrion, Inc.
Chimerix, Inc.
Chongqing Zhifei Biological Products Co., Ltd.
ChronTech Pharma AB
Cocrystal Pharma, Inc.
Cytos Biotechnology AG
CyTuVax B.V.
Dong-A ST Co., Ltd.
Dynavax Technologies Corporation
Ensemble Therapeutics Corporation
Enyo Pharma S.A.S.
F. Hoffmann-La Roche Ltd.
GeneCure LLC
Genexine, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Green Cross Corporation
HEC Pharm Co., Ltd.
Humabs BioMed SA
Ildong Pharmaceutical Co., Ltd.
Immunotope, Inc.
Immunovaccine, Inc.
Inbiopro Solutions Pvt. Ltd.
Indian Immunologicals Limited
iQur Limited
ISA Pharmaceuticals B.V.
Isis Pharmaceuticals, Inc.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Johnson & Johnson
KAEL-GemVax Co., Ltd.
Kineta, Inc.
Leukocare AG
LG Life Science LTD.
Ligand Pharmaceuticals, Inc.
Mologen AG
Mucosis B.V.
MultiCell Technologies, Inc.
Novira Therapeutics, Inc.
Panacea Biotec Limited
Pfenex Inc.
PharmaEssentia Corporation
Profectus BioSciences, Inc.
Redx Pharma Plc
REPLICor Inc.
Romark Laboratories, L.C.
Sanofi Pasteur SA
SEEK Group
Sinovac Biotech Ltd.
Spring Bank Pharmaceuticals, Inc.
TCM Biotech International Corp
TetraLogic Pharmaceuticals
TGV-Laboratories
Theravectys SA
Transgene SA
UAB Profarma
Vaxine Pty Ltd
Viriom Ltd.
VLP Biotech, Inc.
WaterStone Pharmaceuticals, Inc.
Zydus Cadila Healthcare Limited
Skip to top


Hepatic Encephalopathy - Pipeline Review, H2 2016 US$ 2,000.00 Jul, 2016 · 64 pages
Hepatitis C - Pipeline Review, H2 2016 US$ 2,000.00 Sep, 2016 · 523 pages

Ask Your Question

Hepatitis B - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: